Character Biosciences, Bausch + Lomb to collaborate on development of AMD treatments
Click Here to Manage Email Alerts
Key takeaways:
- Character Bio is eligible for payments based on future product sales.
- The collaboration may expand into other ocular conditions.
Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments for age-related macular degeneration, according to a press release.
The collaboration will combine Character Bio’s AI-powered analytical engine and patient data platform with Bausch + Lomb’s “extensive expertise in ophthalmology” to drive development, according to the release. In addition to an upfront payment and annual research funding from Bausch + Lomb, Character Bio is eligible for development and sales-related milestone payments as well as tiered royalties contingent on future product sales. Bausch + Lomb will also make a strategic equity investment in Character Bio, subject to closing conditions.
The collaboration has the potential to expand into other eye conditions, according to the release.
“This collaboration represents a pivotal step in applying a data-driven approach to ophthalmology drug development,” Yehia Hashad, MD, chief medical officer and executive vice president of research and development at Bausch + Lomb, said in the release. “We aim to deliver transformative treatments to patients by uncovering novel disease mechanisms and accelerating the development of targeted therapies for AMD.”
Read more about
Click Here to Manage Email Alerts